Список литературы

[1] Адамян Л.В. Состояние репродуктивной системы у больных доброкачественными опухолями внутренних гениталий и принципы восстановительного лечения//Москва. - 1985. Москва.

[2] El-Balat A. et al. Modern Myoma Treatment in the Last 20 Years: A Review of the Literature//BioMed research international. - 2018. - Т. 2018.

[3] F. R. et al. EMAS position statement: management of uterine fibroids//Maturitas. - 2014. - Т. 79. - N. 1. - С. 106 - 116.

[4] Kubik-Huch R. A. et al. European Society of Urogenital Radiology (ESUR) guidelines: MR imaging of leiomyomas//European radiology. - 2018. - Т. 28. - N. 8. - С. 3125 - 3137.

[5] Grings A. O. et al. Protein expression of estrogen receptors and and aromatase in myometrium and uterine leiomyoma//Gynecologic and obstetric investigation. - 2012. - Т. 73. - N. 2. - С. 113 - 117.

[6] Markowski D. N. et al. HMGA2 and p14Arf: major roles in cellular senescence of fibroids and therapeutic implications//Anticancer research. - 2011. - Т. 31. - N. 3. - С. 753 - 761.

[7] Ciavattini A. et al. Uterine fibroids: pathogenesis and interactions with endometrium and endomyometrial junction//Obstetrics and gynecology international. - 2013. - Т. 2013.

[8] Mittal P. et al. Med12 gain-of-function mutation causes leiomyomas and genomic instability//The Journal of clinical investigation. - 2015. - Т. 125. - N. 8. - С. 3280 - 3284.

[9] Osinovskaya N. S. et al. Frequency and spectrum of MED12 exon 2 mutations in multiple versus solitary uterine leiomyomas from Russian patients//International journal of gynecological pathology. - 2016. - Т. 35. - N. 6. - С. 509 - 515.

[10] Tal R., Segars J. H. The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy//Human reproduction update. - 2013. - Т. 20. - N. 2. - С. 194 - 216.

[11] Сидорова И.С. и др. Современное состояние вопроса о патогенезе, клинике, диагностике и лечении миомы матки у женщин репродуктивного возраста//Акушерство, гинекология и репродукция. - 2012. - Т. 6. - N. 4.

[12] Ren Y. et al. Different effects of epidermal growth factor on smooth muscle cells derived from human myometrium and from leiomyoma//Fertility and sterility. - 2011. - Т. 96. - N. 4. - С. 1015 - 1020.

[13] Plewka D. et al. Expression of VEGF isoforms and their receptors in uterine myomas//Ginekologia polska. - 2016. - Т. 87. - N. 3. - С. 166 - 177.

[14] Baird D. D. et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence//American journal of obstetrics and gynecology. - 2003. - Т. 188. - N. 1. - С. 100 - 107.

[15] Chiaffarino F. et al. Alcohol consumption and risk of uterine myoma: A systematic review and meta analysis//PloS one. - 2017. - Т. 12. - N. 11. - С. e0188355.

[16] Серов В.Н., Сухих Г.Т. Клинические рекомендации. Акушерство и гинекология//М: ГЭОТАР-Медиа. - 4-е изд. - 2017. Москва: Проблемы репродукции.

[17] Donnez J., Donnez O., Dolmans M. M. With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice?//Fertility and Sterility. - 2014. - Т. 102. - N. 3. - С. 640 - 648.

[18] Worldwide A. A. M. I. G. AAGL practice report: practice guidelines for the management of hysteroscopic distending media: (replaces hysteroscopic fluid monitoring guidelines. J Am Assoc Gynecol Laparosc. 2000; 7: 167 - 168.)//Journal of minimally invasive gynecology. - 2013. - Т. 20. - N. 2. - С. 137 - 148.

[19] SOGC clinical practice guideline, The Management of Uterine Leiomyomas, No. 318.

[20] Stewart E. A. et al. Epidemiology of uterine fibroids: a systematic review//BJOG: An International Journal of Obstetrics & Gynaecology. - 2017. - Т. 124. - N. 10. - С. 1501 - 1512.

[21] Zepiridis L. I., Grimbizis G. F., Tarlatzis B. C. Infertility and uterine fibroids//Best Practice & Research Clinical Obstetrics & Gynaecology. - 2016. - Т. 34. - С. 66 - 73.

[22] Parazzini F., Tozzi L., Bianchi S. Pregnancy outcome and uterine fibroids//Best practice & research Clinical obstetrics & gynaecology. - 2016. - Т. 34. - С. 74 - 84.

[23] Munro M. G. et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age//International Journal of Gynecology & Obstetrics. - 2011. - Т. 113. - N. 1. - С. 3 - 13.

[24] Munro M. G. et al. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions//International Journal of Gynecology & Obstetrics. - 2018.

[25] Suzuki A. et al. Differential Diagnosis of Uterine Leiomyoma and Uterine Sarcoma Using Magnetic Resonance Images: A Literature Review//Healthcare. - Multidisciplinary Digital Publishing Institute, 2019. - Т. 7. - N. 4. - С. 158.

[26] Савельева Г.М. и др. Национальное руководство//Акушерство-М.: Гэотар-Медиа. - 2015.

[27] Marret H. et al. Therapeutic management of uterine fibroid tumors: updated French guidelines//European Journal of Obstetrics & Gynecology and Reproductive Biology. - 2012. - Т. 165. - N. 2. - С. 156 - 164.

[28] Fascilla F. D. et al. Ultrasound diagnosis of uterine myomas//Minerva ginecologica. - 2016. - Т. 68. - N. 3. - С. 297 - 312.

[29] Minsart A. F. et al. Does three-dimensional power Doppler ultrasound predict histopathological findings of uterine fibroids? A preliminary study//Ultrasound in obstetrics & gynecology. - 2012. - Т. 40. - N. 6. - С. 714 - 720.

[30] Levine D. J. et al. Sensitivity of myoma imaging using laparoscopic ultrasound compared with magnetic resonance imaging and transvaginal ultrasound//Journal of minimally invasive gynecology. - 2013. - Т. 20. - N. 6. - С. 770 - 774.

[31] Yang T. et al. Sonohysterography: Principles, technique and role in diagnosis of endometrial pathology//World journal of radiology. - 2013. - Т. 5. - N. 3. - С. 81.

[32] A., S. Ultrasonography of uterine leiomyomas//Przeglad menopauzalny = Menopause review. - 2017. - Т. 16. - N. 4. - С. 113.

[33] Dueholm M. et al. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas//American journal of obstetrics and gynecology. - 2002. - Т. 186. - N. 3. - С. 409 - 415.

[34] De La Cruz M. S., Buchanan E. M. Uterine fibroids: diagnosis and treatment//Am Fam Physician. - 2017. - Т. 95. - N. 2. - С. 100 - 107.

[35] Donnez J., Dolmans M. M. Uterine fibroid management: from the present to the future//Human Reproduction Update. - 2016. - Т. 22. - N. 6. - С. 665 - 686.

[36] Серов В.Н., Сухих Г.Т. Клинические рекомендации. Акушерство и гинекология//М: ГЭОТАР-Медиа. - 4-е изд. - 2014. - 1024 С. - 2014. Москва: Проблемы репродукции.

[37] Qin J. et al. Oral contraceptive use and uterine leiomyoma risk: a meta-analysis based on cohort and case-control studies//Archives of gynecology and obstetrics. - 2013. - Т. 288. - N. 1. - С. 139 - 148.

[38] Roberts M. E., Aynardi J. T., Chu C. S. Uterine leiomyosarcoma: A review of the literature and update on management options//Gynecologic oncology. - 2018.

[39] Eder S. et al. Efficacy and safety of oral tranexamic acid in women with heavy menstrual bleeding and fibroids//Women's health. - 2013. - Т. 9. - N. 4. - С. 397 - 403.

[40] Bitzer J. et al. Medical management of heavy menstrual bleeding: a comprehensive review of the literature//Obstetrical & gynecological survey. - 2015. - Т. 70. - N. 2. - С. 115 - 130.

[41] Lukes A. S. et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial//Obstetrics & Gynecology. - 2010. - Т. 116. - N. 4. - С. 865 - 875.

[42] Lethaby A., Duckitt K., Farquhar C. Non steroidal anti-inflammatory drugs for heavy menstrual bleeding//Cochrane database of systematic reviews. - 2013. - N. 1.

[43] Ichigo S. et al. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist//Archives of gynecology and obstetrics. - 2011. - Т. 284. - N. 3. - С. 667 - 670.

[44] Lethaby A. et al. Progesterone or progestogen releasing intrauterine systems for heavy menstrual bleeding//Cochrane Database of Systematic Reviews. - 2015. - N. 4.

[45] Bofill M. R. et al. Cyclical progestogens for heavy menstrual bleeding//The Cochrane database of systematic reviews. - 2019. - Т. 8.

[46] Lethaby A., Puscasiu L., Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids//Cochrane Database of Systematic Reviews. - 2017. - N. 11.

[47] Mas A. et al. Updated approaches for management of uterine fibroids//International journal of women's health. - 2017. - Т. 9. - С. 607.

[48] Zhang Y. et al. The impact of preoperative gonadotropin-releasing hormone agonist treatment on women with uterine fibroids: a meta-analysis//Obstetrical & gynecological survey. - 2014. - Т. 69. - N. 2. - С. 100 - 108.

[49] Tristan M. et al. Mifepristone for uterine fibroids//Cochrane Database of Systematic Reviews. - 2012. - N. 8.

[50] Shen Q. et al. Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis//Fertility and sterility. - 2013. - Т. 100. - N. 6. - С. 1722 - 1726.

[51] Feng C., Meldrum S., Fiscella K. Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone//International Journal of Gynecology & Obstetrics. - 2010. - Т. 109. - N. 2. - С. 121 - 124., doi: 10.1016/j.ijgo.2009.11.019.

[52] Eisinger S. H. et al. Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata//European Journal of Obstetrics & Gynecology and Reproductive Biology. - 2009. - Т. 146. - N. 2. - С. 215 - 218.

[53] Chittawar P. B. et al. Minimally invasive surgical techniques versus open myomectomy for uterine fibroids//Cochrane Database of Systematic Reviews. - 2014. - N. 10.

[54] Sandberg E. M. et al. Reintervention risk and quality of life outcomes after uterine-sparing interventions for fibroids: a systematic review and meta-analysis//Fertility and sterility. - 2018. - Т. 109. - N. 4. - С. 698 - 707.

[55] Kongnyuy E. J., Wiysonge C. S. Interventions to reduce haemorrhage during myomectomy for fibroids//Cochrane Database of Systematic Reviews. - 2014. - N. 8. John Wiley & Sons, Ltd.

[56] ACOG. Leiomyomas P. Uterine Morcellation for Presumed Leiomyomas. - 2019.

[57] Gkrozou F. et al. Hysteroscopy in women with abnormal uterine bleeding: a meta-analysis on four major endometrial pathologies//Archives of gynecology and obstetrics. - 2015. - Т. 291. - N. 6. - С. 1347 - 1354.

[58] Yin X. et al. Hysteroscopic tissue removal systems for the treatment of intrauterine pathology: a systematic review and meta-analysis//Facts, views & vision in ObGyn. - 2018. - Т. 10. - N. 4. - С. 207.

[59] Sesti F. et al. Randomized comparison of total laparoscopic, laparoscopically assisted vaginal and vaginal hysterectomies for myomatous uteri//Archives of gynecology and obstetrics. - 2014. - Т. 290. - N. 3. - С. 485 - 491.

[60] Fonseca M. C. M. et al. Uterine artery embolization and surgical methods for the treatment of symptomatic uterine leiomyomas: a systemic review and meta-analysis followed by indirect treatment comparison//Clinical therapeutics. - 2017. - Т. 39. - N. 7.

[61] Gupta J. K. et al. Uterine artery embolization for symptomatic uterine fibroids//Cochrane Database of Systematic Reviews. - 2014. - N. 12. John Wiley & Sons, Ltd.

[62] Czuczwar P. et al. Comparison of the influence of three fibroid treatment options: Supracervical hysterectomy, ulipristal acetate and uterine artery embolization on ovarian reserve-an observational study//Journal of ovarian research. - 2018. - Т. 11.

[63] Quinn S. D. et al. Safety and five-year re-intervention following magnetic resonance-guided focused ultrasound (MRgFUS) for uterine fibroids//European Journal of Obstetrics & Gynecology and Reproductive Biology. - 2014. - Т. 182. - С. 247 - 251., vol. 182.

[64] Rabinovici J. et al. Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids//Fertility and sterility. - 2010. - Т. 93. - N. 1. - С. 199 - 209.

[65] Carranza-Mamane B. et al. The management of uterine fibroids in women with otherwise unexplained infertility//Journal of Obstetrics and Gynaecology Canada. - 2015. - Т. 37. - N. 3. - С. 277 - 285.

[66] Sagi-Dain L. et al. Pregnancy outcomes in oocyte recipients with fibroids not impinging uterine cavity//Archives of gynecology and obstetrics. - 2017. - Т. 295. - N. 2. - С. 497 - 502.

[67] Wang X. et al. The impact of noncavity-distorting intramural fibroids on the efficacy of in vitro fertilization-embryo transfer: an updated meta-analysis//BioMed research international. - 2018. - Т. 2018.

[68] Radosa M. P. et al. Laparoscopic myomectomy in peri- and post-menopausal women is safe, efficacious and associated with long-term patient satisfaction//European Journal of Obstetrics & Gynecology and Reproductive Biology. - 2012. - Т. 162. - N. 2. - С. 19.

[69] Ulin M. et al. Uterine fibroids in menopause and perimenopause//Menopause. - 2019.

[70] Lethaby A. E., Vollenhoven B. J. An evidence-based approach to hormonal therapies for premenopausal women with fibroids//Best Practice & Research Clinical Obstetrics & Gynaecology. - 2008. - Т. 22. - N. 2. - С. 307 - 331.

[71] Kaganov H., Ades A., Fraser D. S. Preoperative magnetic resonance imaging diagnostic features of uterine leiomyosarcomas: a systematic review//International journal of technology assessment in health care. - 2018. - Т. 34. - N. 2. - С. 172 - 179.

[72] Ludovisi M. et al. Imaging in gynecological disease (15): clinical and ultrasound characteristics of uterine sarcoma//Ultrasound in Obstetrics & Gynecology. - 2019. - Т. 54. - N. 5. - С. 676 - 687.